A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

KMC Hospital in Mangaluru successfully treats Rev Fr Wolfgang Leonhard, a German priest, diagnosed with hypertrophic obstructive cardiomyopathy and complete heart block. The cardiology team implanted ...

The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) and keeping the price ...

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...

Background: Mavacamten, a cardiac myosin inhibitor, is approved across 5 continents for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Long-term data of mavacamten are available from ...

The condition, which currently does not have any approved treatment available in Japan ... is a potential for expansion into further indications, which could include hypertrophic cardiomyopathies.